Quarter
Charts

DERMATA THERAPEUTICS, INC.

DRMA

CIK 0001853816 · Quarterly mode · latest period FY2023 (Q3) (ending 2023-09-30) · sourced from SEC EDGAR

At a glance · FY2023 (Q3)

Revenue
$93K
↑+331.8% +$71Kvs FY2022 (Q3)
Gross Profit
$93K
↑+331.8% +$71Kvs FY2022 (Q3)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Weak
33/100
  • Profitability
    0ROIC -157.8% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 7.66 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    0Asset Turnover 0.01x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +331.8% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Insufficient data

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Stock-based comp (TTM)
$144K
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$8M
everything owned
Total liabilities
$2M
everything owed
Stockholders' equity
$6M
shareholder claim

Recent performance · 24 quarters

Revenue↑+331.8% +$71K
$93K
Net Income↑+46.7% +$1M
$-2M
Free Cash Flow↑+28.5% +$770K
$-2M
Operating Margin↑+9431.2pts
-1953.3%

Drill down

DRMA Sankey

See DERMATA THERAPEUTICS, INC.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

DRMA Charts

24 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

DRMA Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics